The CEOs of Merck, Bristol Myers Squibb and Johnson & Johnson faced a barrage of questions on Capitol Hill from Sen. Bernie Sanders (I-VT) and other members of the Health, Education, Labor and Pensions committee.

The state plans to invest $6.5 million in funds from the 2021 American Rescue Plan Act toward a partnership with nonprofit RIP Medical Debt, which buys bundled medical debt portfolios from providers.

The Delinking Revenue from Unfair Gouging (DRUG) Act would require pharmacy benefit managers that contract with a carrier offering federal health benefits plans to "de-link" the fees they charge insurers from the price of drugs.  

As part of the negotiated settlement, the defendants paid more than $8.3 million in restitution.

The Biden administration took the first step in its Medicare drug price negotiation program for 10 of the costliest prescription drugs, giving drugmakers until March 2 to either accept the government's offer or make a counteroffer.

The Federal Trade Commission launched its inquiry of the 6 largest PBMs in June 2022, after Sen. Chuck Grassley (R-Iowa) had pressed the commission for years to review their role in determining prices for prescriptions like insulin.

After UnitedHealth recently reported 4th-quarter losses due to soaring Medicare Advantage medical costs, Humana has similarly reported steep losses, compared with a $71 million loss during the same period the previous year.

Despite bottlenecks caused by higher than expected dispute resolution claims, the federal No Surprises Act appears to be living up to its name, according to a new survey by AHIP and Blue Cross Blue Shield Association.